Complementing this extracellular targeting approach, eFT508 (Tomivosertib) acts at the translational level by inhibiting phosphorylation of eukaryotic initiation factor 4E (eIF4E) at Ser209, thereby reducing PD-L1 protein synthesis in gastric cancer organoids (59) (Figure 3B). Here, CD274 is linked to gastric cancer.